GE inks deal for imaging antibodies

By staff writers

September 18, 2019 -- GE Healthcare has signed a licensing agreement with Australian biotech company AdAlta to develop antibodies for diagnostic imaging.

AdAlta will screen its human protein therapeutics library to identify antibodies that GE could use as imaging agents, beginning with granzyme B, an enzyme commonly secreted by immune cells in cancer.

The research effort could eventually help in the selection and monitoring of patients receiving immunotherapy, AdAlta said. Financial terms of the agreement were not disclosed.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking